Study 6 of 12Cyclic Glycine-Proline (cGP) literatureInternational journal of pharmaceutics: X · Animal study · Preclinical2026

ZIF-8 nanoplatform coordinating Zn2+ overload and STING activation for enhanced prostate cancer immunotherapy.

A ZIF-8 nanoplatform shows potential in enhancing prostate cancer immunotherapy through Zn2+ overload and STING activation, but human studies are needed.

Read at International journal of pharmaceutics: X Add to compare

Where it sits

this study against the rest of the cyclic glycine-proline (cgp) corpus

Preclinical · this one

Observational

Open-label

Randomised

Reviews

Summary and findings

The study investigates a ZIF-8 nanoplatform for prostate cancer immunotherapy, coordinating Zn2+ overload and STING activation. The platform encapsulates pyrithione, cyclic diguanylate, and ovalbumin to stimulate antitumor immunity. In vitro and in vivo experiments showed activation of STING signaling and tumor regression.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →

Preclinical2026

Abstract

The authors’ words, as International journal of pharmaceutics: X supplied them

Zinc homeostasis dysregulation is a significant feature in prostate cancer (PCa), characterized by a marked decrease in intracellular Zn2+ concentration. High levels of Zn2+ inhibit PCa cell proliferation, enhance drug sensitivity, and are closely linked to antitumor immune activation. Here, zeolitic imidazolate framework-8 (ZIF-8) was employed to encapsulate pyrithione (PT), a Zn2+ ionophore, and cyclic diguanylate (c-di-GMP), a STING agonist, followed by encapsulation with ovalbumin (OVA). In this nanoplatform (PT-c-di-GMP/OVA@ZIF-8), ZIF-8 degrades within the tumor microenvironment (TME) to release Zn2+. Upon cellular uptake, PT facilitates the intracellular transport of extracellular Zn2+. These Zn2+ may act synergistically with c-di-GMP to stimulate the cGAS-STING pathway, while OVA promoting antigen presentation, collectively activating and amplifying antitumor immunity. Both in vitro and in vivo experiments demonstrated that PT-c-di-GMP/OVA@ZIF-8 effectively activates STING signaling and antitumor immune responses, leading to tumor regression. Furthermore, combination therapy with an anti-PD-L1 antibody further enhanced the antitumor efficacy. This study proposes a Zn2+ overload and cGAS-STING pathway-based nanoplatform that activates robust antitumor immunity with a favorable safety profile, showing promise as a candidate strategy for PCa treatment.

Background

Prostate cancer is characterized by dysregulated zinc homeostasis, with decreased intracellular Zn2+ levels. High Zn2+ concentrations can inhibit cancer cell proliferation and enhance drug sensitivity. This study explores a nanoplatform to exploit these properties by coordinating Zn2+ overload and STING pathway activation to enhance antitumor immunity.

Methods

The study utilized a zeolitic imidazolate framework-8 (ZIF-8) to encapsulate pyrithione, a Zn2+ ionophore, cyclic diguanylate (c-di-GMP), a STING agonist, and ovalbumin. The platform was tested in vitro and in vivo for its ability to release Zn2+ in the tumor microenvironment, facilitate intracellular Zn2+ transport, and activate the cGAS-STING pathway.

Results

The nanoplatform effectively activated STING signaling and antitumor immune responses in both in vitro and in vivo models, resulting in tumor regression. The combination therapy with an anti-PD-L1 antibody further enhanced the antitumor efficacy.

Interpretation

The study suggests that the ZIF-8 nanoplatform could be a promising strategy for prostate cancer treatment by leveraging Zn2+ overload and STING activation. However, the clinical significance remains uncertain due to the reliance on preclinical models. Further research is needed to confirm these findings in human trials.

Key findings

ZIF-8 nanoplatform degrades in the tumor microenvironment to release Zn2+.
Intracellular Zn2+ transport is facilitated by pyrithione.
STING signaling activation leads to antitumor immune responses.
Combination with anti-PD-L1 antibody enhances antitumor efficacy.

Limitations

In vitro and in vivo models only, no human data
Potential differences in human zinc homeostasis
Nanoplatform degradation and release dynamics may vary in humans

Elsewhere in the Cyclic Glycine-Proline (cGP) corpus

CScreening of Stereochemically Defined 2,5-Diketopiperazines Identifies Autophagy Inducers without mTORC1 Suppressionbiorxiv-preprint · 2026 · Not reported in abstract.In vitro CDevelopment of a novel electrochemical impedance spectroscopy-based biosensor for bone formation-resorption biomarker determination in body fluids.Bioelectrochemistry (Amsterdam, Netherlands) · 2026 · β-CTX detection range: 10-60 pg mL^-1, LOD: 2.9 pg mL^-1In vitro CReduced mediators released by cyanobacteria during exoelectrogenesis detected using differential pulse voltammetry.Bioelectrochemistry (Amsterdam, Netherlands) · 2026 · Multiple light-enhanced oxidation peaks at 0.1-0.65 V vs. SCE.In vitro CRational design of a sulfonium-stabilized cyclic temporin-SHf as a potential food preservative.Food microbiology · 2026 · Ten-fold increase in antimicrobial potency relative to native peptide.In vitro CGlycodeoxycholic and deoxycholic bile acids impair recognition and spatial memory in adult mice, and reduce central CREB-BDNF signaling and cytokine expression with neuroanatomical specificity.Gut microbes · 2026 · GDCA impaired recognition memory after 10 days.Animal CDiscovery of a novel STING-binding peptide associated with reduced cGAMP-induced inflammatory gene expression.Journal of enzyme inhibition and medicinal chemistry · 2026 · Peptide-1 Kd = 0.15 ± 0.01 μMIn vitro